Startup Betuvax will raise up to 150 million rubles for vaccine development

The company plans to place 10.1 million shares on the VTB platform and more than 5 million on Zorko at a price of 9.86 rubles per share. The date of placement of the last share through private subscription is December 23. The minimum number of securities to acquire is 50.7 thousand.

According to the company’s investment presentation, Betuvax is developing vaccines against cat allergies, against HPV, rotavirus, coronavirus, as well as a vaccine against influenza and Covid. The company characterizes its activities as “design of highly effective antigens.”

Funds raised will be used to conduct preclinical trials and the first phase of clinical trials of a cat allergy vaccine. The funds will also be used to complete pilot trials of vaccines against HPV and rotavirus infection and, if successful, to conduct a preclinical trial. The next step will be obtaining patents.

The company expects its revenue to reach 294 million rubles in 2027 and to reach almost 6 billion rubles in 2032. The investor is promised a further increase in profitability and a 50% return on investment within two weeks through participation in the personal income tax refund program of the Skolkovo Foundation. It also foresees the repurchase of shares at a price of +15% to the placement in three years.

• Betuvax has already raised 255 million rubles from the Artgen group (previously called the Human Stem Cell Institute). The money is intended for the development of technology for the creation of antigens for vaccines, as well as the direct development of vaccines against cat allergies (positive results were obtained at the proof-of-concept stage). Funds have also been invested in the creation of COVID-19 vaccines, a combined flu and Covid vaccine. In addition, an agreement was signed for the contract production of the Betuvax CoV-2 vaccine.
• JSC Betuvax was created following the corporatization of Betuvax LLC in June 2024. Its owners are not disclosed. The general director of the company is Anna Vakhrusheva.
• Before the transformation into JSC, the participants of Betuvax LLC were Artgen (87.67%), Artur Isaev (3.08%), Igor Krasilnikov (3.08%). Alexander Kudryavtsev, Iskch Ventures LLC, Anna Vakhrusheva, Taras Ivanishin and Maria Frolova also had small shares.
• The Human Stem Cell Institute (now Artgen) was founded in 2003. The holding brings together 13 companies in the field of gene therapy, regenerative medicine, genetic diagnostics and consulting. Its portfolio includes 33 developments and 87 patented technologies. In particular, the group includes the company Genetico, which develops genetic tests, solutions for cancer detection and other areas.